Immune Response Induction and New Effector Mechanisms Possibly Involved in Protection Conferred by the Cuban Anti-Meningococcal BC Vaccine

Pérez, Oliver; Lastre, Miriam; Lapinet, José; Bracho, Gustavo; Díaz, Miriam; Zayas, Caridad; Taboada, Carlos; Sierra, Gustavo

doi:10.1128/iai.69.7.4502-4508.2001

Cited by 55 publications

(36 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PorA has been shown to be a major antigen target for both antibodies and T cells in natural and OMV-induced immunity (4,(35)(36)(37)(38)(39). Proliferative T cell responses were also observed after vaccination with the Cuban OMV vaccine (40) based on a different serotype (B:4,P1,19,15).…”

Section: Discussionmentioning

confidence: 74%

“…In addition, we have demonstrated that crossreactive T cell responses were accompanied by the production of both Th1 and Th2 cytokines measured as IFN-␥, IL-4, and IL-10. Parenteral immunization with OMV vaccines has previously been claimed to induce a Th1-biased response (40,44), but a clear association between any defined cytokine profile and protection against meningococcal disease has not yet been established. It has been suggested that a Th1-skewed immune response can be beneficial by promoting enhanced Fc␥R1 expression on phagocytes, neutrophil mobilization, and intracellular bactericidal activity, whereas a more balanced Th1/Th2 response will be necessary to secure the activation and regulation of essential B cell responses such as IgG and IgA production and opsonophagocytosis (45,46).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cellular Immune Responses in Humans Induced by Two Serogroup B Meningococcal Outer Membrane Vesicle Vaccines Given Separately and in Combination

Oftung

Korsvold

Aase

et al. 2016

Clin Vaccine Immunol

View full text Add to dashboard Cite

MenBvac and MeNZB are safe and efficacious outer membrane vesicle (OMV) vaccines against serogroup B meningococcal disease. Antibody responses have previously been investigated in a clinical trial with these two OMV vaccines given separately (25 g/dose) or in combination (12.5 and 12.5 g/dose) in three doses administered at 6-week intervals. Here, we report the results from analyzing cellular immune responses against MenBvac and MeNZB OMVs in terms of antigen-specific CD4 ؉ T cell proliferation and secretion of cytokines. The proliferative CD4؉ T cell responses to the combined vaccine were of the same magnitude as the homologous responses observed for each individual vaccine. The results also showed cross-reactivity in the sense that both vaccine groups receiving separate vaccines responded to both homologous and heterologous OMV antigen when assayed for antigen-specific cellular proliferation. In addition, a multiplex bead array assay was used to analyze the presence of Th1 and Th2 cytokines in cell culture supernatants. The results showed that gamma interferon, interleukin-4 (IL-4), and IL-10 responses could be detected as a result of vaccination with both the MenBvac and the MeNZB vaccines given separately, as well as when given in combination. With respect to cross-reactivity, the cytokine results paralleled the observations made for proliferation. In conclusion, the results demonstrate that cross-reactive cellular immune responses involving both Th1 and Th2 cytokines can be induced to the same extent by different tailor-made OMV vaccines given either separately or in combination with half the dose of each vaccine. N eisseria meningitidis serogroup B vaccines based on outer membrane vesicles (OMVs) from defined serogroup B strains have been shown to be efficacious to control clonal outbreaks in several countries, including Norway, Cuba, and New Zealand (1-3). The PorA protein is the immunodominant antigen in OMV vaccines and elicits protective immune responses (4). PorA shows large sequence variation between strains, and a limitation of OMV vaccines is that they induce mainly strain-specific antibodies (5), but cross-protective antibodies against other B strains have been observed in small children and adults (3, 5). The OMV vaccine MenBvac was developed based on the B:15:P1.7,16 strain representative of the previous meningococcal epidemic in Norway. Based on several clinical trials, this vaccine has been shown to be safe, immunogenic, and to confer protection against meningococcal B disease (6-9). MenBvac has also recently been used to combat an outbreak of serogroup B disease in France demonstrating that OMV vaccines can be efficient against heterologous B strains provided that they are sufficiently immunologically close (10, 11).A similar meningococcal serogroup B OMV vaccine (MeNZB) based on a different strain (B:4:P1.7-2,4) was developed and introduced in 2004 to control the meningococcal epidemic in New Zealand (12)(13)(14) showing more than 70% effectiveness (3). However, in most geographical regions ...

show abstract

Section: Discussionmentioning

confidence: 74%

Section: Discussionmentioning

confidence: 99%

Cellular Immune Responses in Humans Induced by Two Serogroup B Meningococcal Outer Membrane Vesicle Vaccines Given Separately and in Combination

Oftung

Korsvold

Aase

et al. 2016

Clin Vaccine Immunol

View full text Add to dashboard Cite

show abstract

“…Indeed, it is likely that also phagocytic killing plays an important role for protection against meningococcal disease (1,9,44,47). Thus, other techniques, both functional, such as opsonophagocytic (2,33) and whole-blood assay (32), and nonfunctional assays (34,38,55,56), as well as assessment of active (49) or passive protection in animal models (21,51), have been evaluated for providing additional information about the mechanisms of protective immunity or even for providing correlates of protection against group B meningococcal disease.…”

mentioning

confidence: 99%

Protection by Natural Human Immunoglobulin M Antibody to Meningococcal Serogroup B Capsular Polysaccharide in the Infant Rat Protection Assay Is Independent of Complement-Mediated Bacterial Lysis

et al. 2005

View full text Add to dashboard Cite

Neisseria meningitidis, an important cause of bacterial meningitis and septicemia worldwide, is associated with high mortality and serious sequelae. Natural immunity against meningococcal disease develops with age, but the specificity and functional activity of natural antibodies associated with protection are poorly understood. We addressed this question by using a selected subset of prevaccination sera (n ‫؍‬ 26) with convergent or discrepant serum bactericidal activity (SBA) and infant rat protective activity (

show abstract

“…14,34 The VA-MENGOC-BC ® vaccine against N. meningitidis was produced at the Finlay Institute in Havana, Cuba. 35 The outer membrane protein of N. meningitidis was obtained as described by Perez et al 36 conjugation of polysaccharide carbodiimide method…”

Section: Methodsmentioning

confidence: 99%

Immunization and chemical conjugation of Bm95 obtained from Pichia pastoris enhances the immune response against vaccinal protein and Neisseria meningitidis capsular polysaccharide

Rodriguez-Valle¹,

Canan-Hadden²,

Niebla³

2014

VDT

View full text Add to dashboard Cite

Immune Response Induction and New Effector Mechanisms Possibly Involved in Protection Conferred by the Cuban Anti-Meningococcal BC Vaccine

Cited by 55 publications

References 36 publications

Cellular Immune Responses in Humans Induced by Two Serogroup B Meningococcal Outer Membrane Vesicle Vaccines Given Separately and in Combination

Cellular Immune Responses in Humans Induced by Two Serogroup B Meningococcal Outer Membrane Vesicle Vaccines Given Separately and in Combination

Protection by Natural Human Immunoglobulin M Antibody to Meningococcal Serogroup B Capsular Polysaccharide in the Infant Rat Protection Assay Is Independent of Complement-Mediated Bacterial Lysis

Immunization and chemical conjugation of Bm95 obtained from Pichia pastoris enhances the immune response against vaccinal protein and Neisseria meningitidis capsular polysaccharide

Contact Info

Product

Resources

About